



March 2026

ACR Update

ACR staff showing off our new green scrubs!



New Study Enrolling

4DMT 4FRONT-2

Austin Clinical Research is participating in a clinical trial that is enrolling participants recently diagnosed with Wet Age-Related Macular Degeneration (AMD). This Phase 3 study is evaluating a single injection of 4D-150 gene therapy compared to standard of care Eylea injections.

If you were diagnosed with Wet AMD within the past 6 months and received fewer than 5 injections, you may be eligible to participate!

For more information, [click here](#).



March 2026

Enrolling Trials

(Click on each study name for more info!)

Dry Age-Related Macular Degeneration (AMD)

Regeneron R3918-AMD-2326 SIENNA (subcutaneous administration)

Genentech GR44251 GAlette - enrollment reopening soon

Sanofi DF118231

Character Biosciences

Wet Age-Related Macular Degeneration (AMD)

DF117940 Sanofi

Alcon RTE888-E001 Nova-1

Hoffman-La Roche GR40549

4DMT 4D-150-C001 Vector Shedding Substudy

4DMT 4D-150-C004 4FRONT-2

Abbvie ABBV-RGX-314

Diabetic Macular Edema (DME)

Genentech GR46431

Boehringer-Ingelheim 1485-0018 Thulite (oral agent)

Eluminex EBS-105-02 LOTUS-2

Eyepoint EYP-1901

Study Spotlight

Regeneron Sienna

Alternative option to eye injections for Geographic Atrophy

A Phase 3 study for patients with Dry AMD (Age-Related Macular Degeneration) with geographic atrophy (GA). In this study, participants may receive subcutaneous injections that have the potential to slow the growth of GA and prevent or slow down vision loss.